Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment

Published:2021-01-15 Issue:6 Volume:10 Page:588-597
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Hossain Mohammad¹,Tiffany Courtney¹,Tao Yu¹,Barth Aline¹,Marbury Thomas C.²,Preston Richard A.³,Dumont Etienne¹

Affiliation:

1. GlaxoSmithKline Collegeville Pennsylvania USA

2. Orlando Clinical Research Center Orlando Florida USA

3. Clinical Pharmacology Research Unit Division of Clinical Pharmacology University of Miami Department of Medicine Miller School of Medicine University of Miami Clinical and Translational Science Institutes (CTSI) and The Peggy and Harold Katz Family Drug Discovery Center Miami Florida USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.913

Reference15 articles.

1. Type IIA topoisomerase inhibition by a new class of antibacterial agents

2. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

3. Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

4. The metabolism and disposition of GSK2140944 in healthy human subjects

5. Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity;Bioorganic & Medicinal Chemistry Letters;2024-10

2. Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study;Infectious Diseases and Therapy;2023-09

3. Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea;Journal of Antimicrobial Chemotherapy;2023-03-08

4. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters;Clinical and Translational Science;2023-01-23

5. In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections;Antimicrobial Agents and Chemotherapy;2022-12-20